Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone33-1-53-77-44-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$39.60 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/26/2019 (Estimated)
OptionableOptionable
Sanofi (NYSE:SNY) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?
Sanofi declared an annual dividend on Tuesday, February 26th. Stockholders of record on Wednesday, May 8th will be paid a dividend of $1.7395 per share on Friday, May 31st. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. View Sanofi's Dividend History.
How were Sanofi's earnings last quarter?
Sanofi SA (NYSE:SNY) posted its quarterly earnings results on Thursday, February, 7th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.01. The business had revenue of $9 billion for the quarter, compared to analyst estimates of $9 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.06 earnings per share. View Sanofi's Earnings History.
When is Sanofi's next earnings date?
What guidance has Sanofi issued on next quarter's earnings?
Sanofi issued an update on its FY 2019 earnings guidance on Thursday, February, 7th. The company provided EPS guidance of $6.43-6.61 for the period.
What price target have analysts set for SNY?
14 equities research analysts have issued twelve-month price targets for Sanofi's stock. Their forecasts range from $50.00 to $55.00. On average, they expect Sanofi's stock price to reach $52.50 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for Sanofi.
What is the consensus analysts' recommendation for Sanofi?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.
What are Wall Street analysts saying about Sanofi stock?
Here are some recent quotes from research analysts about Sanofi stock:
- 1. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)
- 2. According to Zacks Investment Research, "Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. It has several new products in its portfolio and candidates in its pipeline that can boost long-term growth. In fact, Sanofi’s product launches are now delivering revenues greater than the loss of exclusivity impact. Particularly, we are optimistic about Dupixent’s sales prospects, which could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare units has also improved lately. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares of Sanofi have outperformed the industry in the past six months. Estimates have gone down slightly ahead of Q4 earnings release. Sanofi has a mixed record of earnings surprises in recent quarters." (2/5/2019)
Has Sanofi been receiving favorable news coverage?
Media coverage about SNY stock has trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sanofi earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
What other stocks do shareholders of Sanofi own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), General Electric (GE), AT&T (T), Bank of America (BAC), Pfizer (PFE), Alibaba Group (BABA), Merck & Co., Inc. (MRK), Exxon Mobil (XOM) and AbbVie (ABBV).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 62)
- Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
Who are Sanofi's major shareholders?
Sanofi's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (0.90%), Fisher Asset Management LLC (0.64%), FMR LLC (0.36%), Bank of America Corp DE (0.15%), Macquarie Group Ltd. (0.13%) and BlackRock Inc. (0.10%). View Institutional Ownership Trends for Sanofi.
Which institutional investors are selling Sanofi stock?
SNY stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, BlackRock Inc., Tocqueville Asset Management L.P., Brandes Investment Partners LP, Renaissance Group LLC, Mondrian Investment Partners LTD, Macquarie Group Ltd. and Freestone Capital Holdings LLC. View Insider Buying and Selling for Sanofi.
Which institutional investors are buying Sanofi stock?
SNY stock was purchased by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, FMR LLC, United Services Automobile Association, Fisher Asset Management LLC, Bank of Montreal Can, Aviance Capital Management LLC, Oregon Public Employees Retirement Fund and Edge Capital Group LLC. View Insider Buying and Selling for Sanofi.
How do I buy shares of Sanofi?
Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sanofi's stock price today?
One share of SNY stock can currently be purchased for approximately $45.41.
How big of a company is Sanofi?
Sanofi has a market capitalization of $113.89 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis.
What is Sanofi's official website?
How can I contact Sanofi?
Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]
MarketBeat Community Rating for Sanofi (NYSE SNY)
| Community Ranking: | | 2.2 out of 5 ( ) |
| Outperform Votes: | | 395 (Thanks for Voting!) |
| Underperform Votes: | | 500 (Thanks for Voting!) |
| Total Votes: | | 895 |
